CClinicalTrials.gg
Status unknownNCT03171727Updated Jan 8, 2019

Low Molecular Weight Heparin for the Prevention of Early TIPS Dysfunction

An interventional study of low molecular weight heparin in Liver Cirrhosis and Portal Hypertension, sponsored by West China Hospital. Status unknown at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2019-01-08.

Sponsored by West China Hospital · Not applicable, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Jan 2019), so the status shown — last known as Recruiting — may be out of date.
Phase
Not applicable
Study type
Interventional
Enrollment
117
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Study summary

Transjugular intrahepatic portosystemic shunt (TIPS) dysfunction is defined as a loss of decompression of the portal venous system due to occlusion or stenosis of the TIPS. Occlusion of the TIPS can either be due to thrombosis or hyperplasia of the intima. Thrombosis of the TIPS usually occurs early and can happen within 24 hours of TIPS creation. The frequency of this complication is on the order of 10%-15% when bare stents are used. Post-TIPS short-term low molecular weight heparin (LMWH) was used to prevent the early thrombosis formation. Weather post-TIPS LMWH was necessary when polytetrafluoroethylene-covered stent was used during TIPS creation was not answered. The present study was designed to evaluate the effect of short-term use of LMWH on early TIPS dysfunction.

02

Conditions studied

  • Liver Cirrhosis
  • Portal Hypertension
03

In context

Liver Cirrhosis

1,642 studies on the registry are indexed under Liver Cirrhosis; 358 are open to participants now.

This study's planned enrollment of 117 is above the median of 72 across 995 interventional studies indexed under Liver Cirrhosis.

Browse Liver Cirrhosis studies →

Lead sponsor

West China Hospital is the lead sponsor of 483 studies on the registry; 240 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  1. Diagnosis of liver cirrhosis
  2. Technical success of TIPS was achieved.

Exclusion criteria

Exclusion Criteria:

  1. Non-cirrhotic portal hypertension
  2. Portal vein thrombosis
  3. Budd-Chiari syndrome
  4. Pregnancy
  5. Contradictions to anticoagulation therapy
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
117 participants (estimated)

Study arms

  • Experimental
    study group

    After TIPS procedure was performed, low molecular weight heparin was given for three days.

    Drug: low molecular weight heparin

  • No intervention
    control group

    After TIPS procedure was performed, no low molecular weight heparin was given.

Interventions

  • Druglow molecular weight heparin

    After TIPS procedure was performed, low molecular weight heparin was given for three days.

06

What researchers measure

Primary outcomes

  1. TIPS patency rate

    Analysis

    Time frame: one year

Secondary outcomes

  1. LMWH-related complication

    Analysis

    Time frame: one month

  2. Mortality rate

    Analysis

    Time frame: one year

07

Study locations

1 of 1 sites recruiting
  • West china Hospital
    Chengdu, China
    Recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jan 8, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03171727
Lead sponsor
West China Hospital
Responsible party
luo xuefeng (attending doctor, West China Hospital) — Principal investigator
First posted
May 31, 2017
Start date
Jun 1, 2017
Primary completion
May 15, 2019 (estimated)
Completion
Dec 30, 2019 (estimated)
Last update
Jan 8, 2019

Study contacts

xuefeng luo
Contact
luo_xuefeng@yeah.net
02885422311
xuefeng luo
principal investigator · Sichuan University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Jan 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion